# Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

> **NCT01217749** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 71 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Prolymphocyctic Leukemia
- Richter's Transformation

## Interventions

- **DRUG:** PCI-32765
- **DRUG:** ofatumumab

## Key facts

- **NCT ID:** NCT01217749
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-06
- **Final completion:** 2014-05
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2015-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217749, "Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01217749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*